ID: ALA2430727

Max Phase: Preclinical

Molecular Formula: C20H19ClN4O2

Molecular Weight: 382.85

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(C(=O)O)cc1-c1cnc(N)c(N[C@H](C)c2ccc(Cl)cc2)n1

Standard InChI:  InChI=1S/C20H19ClN4O2/c1-11-3-4-14(20(26)27)9-16(11)17-10-23-18(22)19(25-17)24-12(2)13-5-7-15(21)8-6-13/h3-10,12H,1-2H3,(H2,22,23)(H,24,25)(H,26,27)/t12-/m1/s1

Standard InChI Key:  ARFUEGGWDJJGFD-GFCCVEGCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 382.85

Molecular Weight (Monoisotopic): 382.1197

AlogP: 4.56

#Rotatable Bonds: 5

Polar Surface Area: 101.13

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.18

CX Basic pKa: 1.82

CX LogP: 4.32

CX LogD: 1.26

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.60

Np Likeness Score: -1.00

References

1. Fauber BP, Dragovich PS, Chen J, Corson LB, Ding CZ, Eigenbrot C, Giannetti AM, Hunsaker T, Labadie S, Liu Y, Liu Y, Malek S, Peterson D, Pitts K, Sideris S, Ultsch M, VanderPorten E, Wang J, Wei B, Yen I, Yue Q..  (2013)  Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase.,  23  (20): [PMID:24012183] [10.1016/j.bmcl.2013.08.060]

2. Granchi C, Fancelli D, Minutolo F..  (2014)  An update on therapeutic opportunities offered by cancer glycolytic metabolism.,  24  (21): [PMID:25288186] [10.1016/j.bmcl.2014.09.041]

Source

Source(1):

• Scientific Literature